Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Melanoma and Skin Cancer

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

N Engl J Med.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J

doi: 10.1056/NEJMoa1709684.

Melanoma and Skin Cancer

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

Melanoma Res

Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D

doi: 10.1097/CMR.0000000000000744

Melanoma and Skin CancerImmunotherapy

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma

JAMA Ophthalmol.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ

Melanoma and Skin Cancer

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival

JAMA Dermatol.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C, for MelBase.

doi: 10.1001/jamadermatol.

Melanoma and Skin Cancer

Prolonged Overall Survival Following Metastasectomy in Stage IV Melanoma

J Eur Acad Dermatol Venereol.

Elias ML, Behbahani S, Maddukuri S, John AM, Schwartz RA, Lambert WC

doi: 10.1111/jdv.15667.

Melanoma and Skin CancerAutoimmune Disease

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Lancet.

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C

doi: 10.1016/S0140-6736

Melanoma and Skin Cancer

GNAQ and GNA11 mutant non-uveal melanoma, a subtype distinct from both cutaneous and uveal melanoma

Br J Dermatol.

Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, Hassel JC, Herbst R, Utikal JS, Weide B, Gutzmer R, Meier F, Koelsche C, Hadaschik E, Sucker A, Reis H, Merkelbach-Bruse S, Siewert M, Sahm F, von Deimling A, Cosgarea I, Zimmer L, Schadendorf D, Schilling B, Griewank KG

doi: 10.1111/bjd.18947.

Melanoma and Skin Cancer

Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma

J Eur Acad Dermatol Venereol.

Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A, Montaudié H, Lacour JP, Passeron T, Andea AA, Ilie M, Hofman P

doi: 10.1111/jdv.16016.

Melanoma and Skin Cancer

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Ann Surg Oncol.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group

doi: 10.1245/s10434-017-6072-3.

Related content

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival

Prolonged Overall Survival Following Metastasectomy in Stage IV Melanoma

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

GNAQ and GNA11 mutant non-uveal melanoma, a subtype distinct from both cutaneous and uveal melanoma

Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases